Physician profile
Mairaj Uddin
NPI 1144329285
$3,384.61
in general payments reported to CMS, 2019-2025
31 companies · $624 in 2025
The $624 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $312 · 2021: $364 · 2022: $453 · 2023: $389 · 2024: $584 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,596.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $636.03 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Cook Medical LLC | $299.99 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $291.10 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $250.52 | 2019-2025 | |
| Abbvie INC. | $208.32 | 2021-2025 | Vraylar |
| Novartis Pharmaceuticals Corporation | $170.33 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.15 | 2019-2025 | Jardiance |
| Amgen INC. | $160.24 | 2019-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $153.18 | 2019-2022 | |
| Lilly USA, LLC | $153.07 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Janssen Pharmaceuticals, INC | $139.90 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $90.28 | 2025 | Watchman Access System |
| Phathom Pharmaceuticals, INC. | $88.40 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $73.32 | 2019-2020 | |
| Abbott Laboratories | $71.96 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $62.22 | 2019-2025 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $54.52 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $40.63 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $37.36 | 2019-2022 | |
| Lundbeck LLC | $34.92 | 2023-2024 | Rexulti |
| Genzyme Corporation | $30.72 | 2025 | |
| Arbor Pharmaceuticals, INC. | $26.73 | 2019 | |
| Atricure, INC. | $25.81 | 2025 | Atriclip Laa Exclusion System |
| Inogen, INC. | $20.60 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.12 | 2024 | |
| Ethicon US, LLC | $15.75 | 2019 | |
| Si-Bone, INC. | $14.39 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.09 | 2024 | |
| Allergan, INC. | $13.57 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.93 | 2023 | Quviviq |
| Sanofi Pasteur INC. | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mairaj Uddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.